FEBS Open
TRANSCEND-T2D-1 (NCT06354660), the program's first trial, reported topline results March 19, 2026, with full publication in The Lancet in June
The most impressive and lasting results happen when it's combined with a healthy diet and regular physical activity
While both peptides participate in broad regulatory signaling networks, their primary molecular targets and mechanisms remain distinct, making the blend useful for comparative investigation of multiple peptide-mediated pathways
Whichever the measure, the real goal is to get out of the obese range, not necessarily to get out of the overweight range
Fortunately , at IUVENTUS MEDICAL CENTER, our specialized weight loss programs utilize advanced GLP-1 injectionsincluding Semaglutide, Tirzepatide, and Retatrutideto help you achieve lasting results